Adherex to Hold 2Q06 Financial Results Conference Call on Aug. 10, 2006

- - Live internet webcast to be available at www.adherex.com - -

Research Triangle Park, NC, August 2, 2006 - - Adherex Technologies Inc. (AMEX:ADH, TSX:AHX), a biopharmaceutical company with a broad portfolio of oncology products under development, announced today that it will release its second quarter 2006 financial results on Wednesday, August 9, 2006, followed by a conference call to discuss the results and provide a corporate update on Thursday, August 10, 2006 at 10 a.m. EST. Adherex’s Chairman and CEO Dr. William Peters and Chief Financial Officer Jim Klein will host the call.

To listen to a live or archived version of the audio webcast, investors should log on to the Adherex website (www.adherex.com) where a link to the call will be available. Adherex’s second quarter 2006 financial results conference call can also be heard by dialing (877) 704-5386 in the U.S. and Canada and (913) 312-1302 for international callers (passcode 3878944). A telephone replay will be available starting at 1 p.m. EST on August 10, 2006 and ending at midnight EST on Tuesday, August 15, 2006. To access the telephone replay, dial (888) 203-1112 if calling from the U.S. or Canada or (719) 457-0820 from international locations. Please refer to replay passcode 3878944.

About Adherex Technologies
Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in the clinical stage of development, including ADH-1 (Exherin™), eniluracil and sodium thiosulfate (STS). ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at www.adherex.com.

Contact Information

Melissa Matson

Director, Corporate Communications

Adherex Technologies Inc.

Contact via E-mail